All News
Filter News
Found 61 articles
-
Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
4/10/2021
Ultimovacs ASA, announced that it is presenting a poster on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company’s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021.
-
Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
2/18/2021
Start of TET clinical program supports Ultimovacs’ goal of becoming a leader in cancer vaccine development
-
Ultimovacs ASA: Fourth Quarter 2020 Result Presentation
2/17/2021
Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announces its fourth quarter 2021 results
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Ultimovacs Announces Phase II DOVACC Collaboration Study in Ovarian Cancer With the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca
1/11/2021
Ultimovacs ASA, announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
12/22/2020
Ultimovacs ASA, announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Company’s proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.
-
Clinical Catch-Up: December 7-11
12/14/2020
It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates. -
Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma
12/10/2020
Ultimovacs ASA, announced positive five-year Overall Survival data from the Phase I trial evaluating the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor, ipilimumab, in patients with metastatic malignant melanoma.
-
BioSpace Movers & Shakers, Nov. 27
11/27/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ultimovacs Announces the Appointment of Ton Berkien as Chief Business Officer
11/24/2020
Ultimovacs ASA, announced that Ton Berkien will join Ultimovacs’ management team as Chief Business Officer, effective December 1, 2020.
-
Ultimovacs Announces Third Quarter 2020 Result Presentation
11/12/2020
Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announces its third quarter 2020 results
-
Ultimovacs Announces Acceptance of Publication in ‘Frontiers in Immunology’ Featuring Positive Results From Phase I Trial Evaluating UV1 in Non-Small Cell Lung Cancer
11/2/2020
Ultimovacs ASA, announced the acceptance of publication in Frontiers in Immunology, outlining the positive long-term follow-up data from the company’s Phase I trial evaluating its proprietary universal cancer vaccine, UV1, in non-small cell lung cancer.
-
Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer
10/19/2020
Ultimovacs ASA, announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer.
-
BioSpace Global Roundup, Oct. 1
10/1/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
9/30/2020
Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced positive topline results from the first cohort of 20 patients in its ongoing US-based Phase I clinical trial evaluating the Company’s lead candidate, UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first line treatment in patients with metastatic malignant melanoma.
-
Ultimovacs ASA: Second Quarter 2020 Result Presentation
8/21/2020
Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announces its second quarter 2020 results
-
BioSpace Global Roundup, Aug. 20
8/20/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma
8/18/2020
Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announced that patient enrollment has been completed in the ongoing US-based Phase I clinical trial testing Ultimovacs’ lead candidate, UV1, in combination with pembrolizumab as first line treatment in patients with metastatic malignant melanoma.
-
New $1.5 Billion Oslo Cancer Cluster Innovation Park Opens
8/17/2015